What are the treatment options for pruritus in patients with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Treatment of pruritus in patients with impaired renal function should prioritize non-pharmacological measures, followed by pharmacological approaches, with gabapentin being a viable option, as evidenced by recent studies 1.

Non-Pharmacological Measures

Non-pharmacological measures should be tried first, including:

  • Using mild soaps
  • Applying emollients
  • Avoiding hot baths
  • Wearing loose cotton clothing These measures can help alleviate pruritus symptoms and improve quality of life.

Pharmacological Management

For pharmacological management, the following options can be considered:

  • Topical therapies like menthol 1% in aqueous cream or capsaicin 0.025% cream
  • Systemic options like gabapentin (100-300mg after dialysis) or pregabalin (25-75mg daily, adjusted for renal function)
  • Antihistamines such as diphenhydramine (25-50mg at bedtime) or hydroxyzine (25mg 2-3 times daily), though these should be used cautiously due to potential accumulation in renal failure
  • Opioid antagonists like naltrexone (50mg daily) can be useful when other treatments fail
  • Mirtazapine (15-30mg at bedtime) may provide dual benefits of itch relief and improved sleep

Recent Developments

Recent studies have shown that difelikefalin, a highly selective kappa opioid receptor agonist, has significant improvement in pruritis in some patients undergoing hemodialysis 1. However, more evidence is needed to fully understand its efficacy and safety in this population.

Considerations

When prescribing medications for patients with impaired renal function, it is essential to consider the potential for adverse effects, such as QT prolongation and altered pharmacokinetics 1. Additionally, caution is warranted when prescribing SSRIs due to their adverse-effect profile and lack of consistent benefit in this population 1.

From the Research

Treatment Options for Pruritus in Patients with Impaired Renal Function

  • The treatment of pruritus in patients with impaired renal function is challenging due to limited therapeutic options 2.
  • Topical treatment with or without anti-inflammatory compounds and systemic treatment with gabapentin, μ-opioid receptor antagonists, and κ-agonists are commonly used approaches 2.
  • Other treatment options include drugs with anti-inflammatory action, phototherapy, and acupuncture 2.

Role of κ-Opioid Receptor Agonists in Treating Uremic Pruritus

  • κ-Opioid receptor agonists, such as nalfurafine, difelikefalin, and nalbuphine, have shown promise in reducing itching symptoms in patients with refractory uremic pruritus 3, 4, 5.
  • Nalfurafine has been found to be effective and safe in treating uremic pruritus in patients undergoing hemodialysis, with significant reductions in worst itching, itching intensity, and sleep disturbances 4, 5.

Safety and Efficacy of Nalfurafine

  • Nalfurafine has been shown to be well-tolerated, with most adverse drug reactions being mild and resolving quickly 5, 6.
  • Long-term studies have found no evidence of abuse liability or physical dependence with nalfurafine use in hemodialysis patients 6.
  • Nalfurafine has also been found to be effective in treating refractory pruritus in peritoneal dialysis patients and chronic liver disease patients 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Uremic pruritus.

Kidney international, 2015

Research

[Clinical Research Progress on Using κ-Opioid Receptor Agonists to Treat Uremic Pruritus].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2024

Research

One year long-term study on abuse liability of nalfurafine in hemodialysis patients.

International journal of clinical pharmacology and therapeutics, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.